Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of this study is to estimate the incidence of ocular adverse events (AEs) in patients with CNV secondary to AMD who are treated with 0.3 and/or 0.5 mg intravitreal ranibizumab.
Critère d'inclusion
- Male and female patients ≥50 years of age with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)